. (APPA)
- - (-)
Market Cap: -
As of 12/31/69 07:00 PM EST. Market closed.
. (APPA)
-
- (-)
Market Cap: -
As of 12/31/69 07:00 PM EST. Market closed.
Add to Portfolio
... read more
COMPANY PROFILE
Sector
Industry
URL
Address
.
Sector
Industry
URL
Address
.
PRICE CHART FOR
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
-
Days Range
- - -
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
Open
-
Previous Close
-
Days Range
- - -
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
FINANCIAL STATEMENTS FOR
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Duarte Ira | EVP, Chief Financial Officer | Apr 19, 2024 | Option Exercise | $2.64 | 1,122 | 2,962 | 87,752 | Apr 19, 2024, 05:48 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2024 | Option Exercise | $2.15 | 756 | 1,625 | 55,907 | Jan 16, 2024, 05:19 PM |
| Forbes William P | EVP, Chief Development Officer | Nov 17, 2023 | Buy | $1.09 | 25,000 | 27,250 | 79,000 | Nov 21, 2023, 12:19 PM |
| Forbes William P | EVP, Chief Development Officer | Nov 16, 2023 | Buy | $0.94 | 50,000 | 46,995 | 54,000 | Nov 20, 2023, 10:07 AM |
| Collard Craig A | Chief Executive Officer | Nov 16, 2023 | Buy | $0.92 | 150,000 | 137,970 | 186,496 | Nov 17, 2023, 12:37 PM |
| Duarte Ira | EVP, Chief Financial Officer | Nov 16, 2023 | Buy | $0.89 | 85,000 | 75,599 | 85,000 | Nov 17, 2023, 12:36 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2023 | Option Exercise | $0.72 | 860 | 619 | 54,822 | Oct 17, 2023, 07:57 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 25, 2023 | Option Exercise | $1.51 | 14,743 | 22,262 | 53,198 | Oct 17, 2023, 07:57 PM |
| Collard Craig A | Chief Executive Officer | Aug 22, 2023 | Option Exercise | $1.65 | 692 | 1,142 | 36,496 | Aug 24, 2023, 04:09 PM |
| Morgan Adam | Director | Jul 21, 2023 | Buy | $1.37 | 2,486,744 | 3,406,839 | 6,986,744 | Jul 25, 2023, 04:22 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2023 | Option Exercise | $1.31 | 2,012 | 2,636 | 33,754 | Jul 17, 2023, 05:51 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2023 | Option Exercise | $1.31 | 860 | 1,127 | 25,310 | Jul 17, 2023, 05:51 PM |
| Collard Craig A | Chief Executive Officer | May 22, 2023 | Option Exercise | $1.45 | 691 | 1,002 | 37,188 | May 24, 2023, 05:04 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2023 | Option Exercise | $2.88 | 2,012 | 5,795 | 29,952 | Apr 17, 2023, 05:28 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2023 | Option Exercise | $2.88 | 2,012 | 5,795 | 46,648 | Apr 17, 2023, 05:27 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2023 | Option Exercise | $2.88 | 860 | 2,477 | 23,685 | Apr 17, 2023, 05:27 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2023 | Option Exercise | $2.88 | 1,417 | 4,081 | 28,330 | Apr 17, 2023, 05:26 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 26,150 | Jan 17, 2023, 05:37 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 31, 2022 | Option Exercise | $3.27 | 1,654 | 5,413 | 22,348 | Jan 17, 2023, 05:37 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2023 | Option Exercise | $3.17 | 5,219 | 16,544 | 177,989 | Jan 17, 2023, 05:36 PM |
| Quart Barry D | Chief Executive Officer | Oct 31, 2022 | Option Exercise | $3.27 | 1,655 | 5,416 | 163,441 | Jan 17, 2023, 05:36 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 42,846 | Jan 17, 2023, 05:36 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2023 | Option Exercise | $3.17 | 1,013 | 3,211 | 22,061 | Jan 17, 2023, 05:35 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2023 | Option Exercise | $3.17 | 2,012 | 6,378 | 23,933 | Jan 17, 2023, 05:34 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 31, 2022 | Option Exercise | $3.27 | 1,655 | 5,416 | 20,131 | Jan 17, 2023, 05:34 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 20,694 | Oct 17, 2022, 04:38 PM |
| Quart Barry D | Chief Executive Officer | Oct 13, 2022 | Option Exercise | $3.76 | 5,219 | 19,623 | 161,786 | Oct 17, 2022, 04:38 PM |
| POYHONEN JOHN | President & CCO | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 39,044 | Oct 17, 2022, 04:37 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2022 | Option Exercise | $3.76 | 861 | 3,237 | 20,589 | Oct 17, 2022, 04:36 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 13, 2022 | Option Exercise | $3.76 | 2,012 | 7,565 | 18,476 | Oct 17, 2022, 04:36 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 16,892 | Jul 15, 2022, 04:58 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 29, 2022 | Option Exercise | $3.84 | 1,505 | 5,782 | 13,090 | Jul 15, 2022, 04:58 PM |
| Quart Barry D | Chief Executive Officer | Jul 13, 2022 | Option Exercise | $3.01 | 5,219 | 15,709 | 147,237 | Jul 15, 2022, 04:57 PM |
| Quart Barry D | Chief Executive Officer | Apr 29, 2022 | Option Exercise | $3.84 | 1,504 | 5,778 | 132,688 | Jul 15, 2022, 04:57 PM |
| POYHONEN JOHN | President & CCO | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 35,242 | Jul 15, 2022, 04:56 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2022 | Option Exercise | $3.01 | 860 | 2,589 | 18,965 | Jul 15, 2022, 04:55 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jul 13, 2022 | Option Exercise | $3.01 | 2,012 | 6,056 | 14,674 | Jul 15, 2022, 04:55 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 29, 2022 | Option Exercise | $3.84 | 1,504 | 5,778 | 12,376 | May 04, 2022, 07:01 PM |
| MANHARD KIMBERLY | EVP, Drug Development | May 03, 2022 | Sale | $4.76 | 1,504 | 7,154 | 10,872 | May 04, 2022, 07:01 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 11,585 | Apr 15, 2022, 05:06 PM |
| Quart Barry D | Chief Executive Officer | Apr 13, 2022 | Option Exercise | $6.07 | 5,219 | 31,679 | 131,184 | Apr 15, 2022, 05:05 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 31,440 | Apr 15, 2022, 05:04 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2022 | Option Exercise | $6.07 | 860 | 5,220 | 17,340 | Apr 15, 2022, 05:03 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2022 | Option Exercise | $6.07 | 2,012 | 12,213 | 10,872 | Apr 15, 2022, 05:03 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 7,783 | Jan 14, 2022, 05:09 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2022 | Option Exercise | $8.30 | 5,219 | 43,318 | 116,635 | Jan 14, 2022, 05:08 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 27,638 | Jan 14, 2022, 05:07 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2022 | Option Exercise | $8.30 | 966 | 8,018 | 15,716 | Jan 14, 2022, 05:06 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2022 | Option Exercise | $8.30 | 2,012 | 16,700 | 7,070 | Jan 14, 2022, 05:05 PM |
| POYHONEN JOHN | President & CCO | Oct 29, 2021 | Option Exercise | $9.36 | 817 | 7,646 | 23,836 | Dec 23, 2021, 06:59 PM |
| Christian Waage | Director | Dec 21, 2021 | Sale | $9.73 | 300 | 2,920 | 3,200 | Dec 23, 2021, 06:58 PM |
| Johnson Craig A | Director | Dec 21, 2021 | Sale | $9.73 | 250 | 2,432 | 2,840 | Dec 23, 2021, 06:57 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 3,981 | Oct 15, 2021, 04:26 PM |
| Quart Barry D | Chief Executive Officer | Oct 13, 2021 | Option Exercise | $10.55 | 963 | 10,160 | 102,086 | Oct 15, 2021, 04:25 PM |
| POYHONEN JOHN | President & CCO | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 23,019 | Oct 15, 2021, 04:24 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Oct 13, 2021 | Option Exercise | $10.55 | 191 | 2,015 | 14,197 | Oct 15, 2021, 04:23 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Oct 13, 2021 | Option Exercise | $10.55 | 433 | 4,568 | 3,268 | Oct 15, 2021, 04:22 PM |
| Christian Waage | Director | Sep 21, 2021 | Sale | $12.31 | 300 | 3,692 | 3,500 | Sep 23, 2021, 04:30 PM |
| Johnson Craig A | Director | Sep 21, 2021 | Sale | $12.30 | 250 | 3,074 | 3,090 | Sep 23, 2021, 04:29 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 3,164 | Jul 15, 2021, 04:52 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,530 | 21,263 | 2,347 | Jul 15, 2021, 04:52 PM |
| Quart Barry D | Chief Executive Officer | Jul 13, 2021 | Option Exercise | $13.48 | 963 | 12,981 | 99,403 | Jul 15, 2021, 04:50 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,529 | 21,249 | 96,721 | Jul 15, 2021, 04:50 PM |
| POYHONEN JOHN | President & CCO | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 22,202 | Jul 15, 2021, 04:49 PM |
| POYHONEN JOHN | President & CCO | Apr 30, 2021 | Option Exercise | $13.90 | 971 | 13,494 | 21,385 | Jul 15, 2021, 04:49 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jul 13, 2021 | Option Exercise | $13.48 | 191 | 2,575 | 13,836 | Jul 15, 2021, 04:48 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 30, 2021 | Option Exercise | $13.90 | 1,530 | 21,263 | 13,475 | Jul 15, 2021, 04:48 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jul 13, 2021 | Option Exercise | $13.48 | 433 | 5,837 | 2,451 | Jul 15, 2021, 04:47 PM |
| Johnson Craig A | Director | Jun 21, 2021 | Sale | $15.20 | 250 | 3,801 | 3,340 | Jun 22, 2021, 05:05 PM |
| Christian Waage | Director | Apr 15, 2021 | Sale | $17.51 | 300 | 5,254 | 4,100 | Apr 16, 2021, 08:59 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 817 | Apr 15, 2021, 04:55 PM |
| Quart Barry D | Chief Executive Officer | Apr 13, 2021 | Option Exercise | $16.66 | 963 | 16,044 | 95,192 | Apr 15, 2021, 04:54 PM |
| POYHONEN JOHN | President & CCO | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 20,414 | Apr 15, 2021, 04:53 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Apr 13, 2021 | Option Exercise | $16.66 | 191 | 3,182 | 11,945 | Apr 15, 2021, 04:52 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Apr 13, 2021 | Option Exercise | $16.66 | 433 | 7,214 | 1,634 | Apr 15, 2021, 04:51 PM |
| Johnson Craig A | Director | Apr 06, 2021 | Sale | $17.22 | 250 | 4,305 | 3,590 | Apr 07, 2021, 05:04 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 13, 2021 | Option Exercise | $18.16 | 423 | 7,682 | 827 | Jan 15, 2021, 04:30 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 14, 2021 | Sale | $18.09 | 827 | 14,960 | 0 | Jan 15, 2021, 04:30 PM |
| Quart Barry D | Chief Executive Officer | Jan 13, 2021 | Option Exercise | $18.16 | 963 | 17,488 | 91,909 | Jan 15, 2021, 04:29 PM |
| POYHONEN JOHN | President & CCO | Jan 13, 2021 | Option Exercise | $18.16 | 433 | 7,863 | 19,597 | Jan 15, 2021, 04:27 PM |
| Peraza Lisa | VP, Chief Accounting Officer | Jan 13, 2021 | Option Exercise | $18.16 | 227 | 4,122 | 11,584 | Jan 15, 2021, 04:26 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Jan 13, 2021 | Option Exercise | $18.16 | 433 | 7,863 | 817 | Jan 15, 2021, 04:25 PM |
| Szekeres David Leslie | EVP, Chief Operating Officer | Jan 08, 2021 | Sale | $19.66 | 3,571 | 70,219 | 0 | Jan 08, 2021, 06:07 PM |
| POYHONEN JOHN | President & CCO | Oct 30, 2020 | Option Exercise | $11.65 | 637 | 7,423 | 18,780 | Dec 23, 2020, 04:24 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Dec 22, 2020 | Option Exercise | $13.00 | 10,000 | 130,000 | 10,000 | Dec 23, 2020, 04:23 PM |
| MANHARD KIMBERLY | EVP, Drug Development | Dec 22, 2020 | Sale | $20.00 | 10,000 | 200,000 | 0 | Dec 23, 2020, 04:23 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2020 | Option Exercise | $12.12 | 1,158 | 14,036 | 89,226 | Oct 15, 2020, 04:23 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 30, 2020 | Option Exercise | $12.12 | 1,158 | 14,036 | 1,158 | May 01, 2020, 06:48 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | May 01, 2020 | Sale | $13.97 | 1,158 | 16,176 | 0 | May 01, 2020, 06:48 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29, 2019 | Option Exercise | $13.00 | 24,000 | 312,000 | 24,000 | Dec 03, 2019, 06:30 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29, 2019 | Sale | $26.00 | 24,000 | 624,000 | 0 | Dec 03, 2019, 06:30 PM |
| TANG KEVIN C | Director | Oct 04, 2019 | Buy | $17.50 | 285,714 | 4,999,995 | 5,799,810 | Oct 07, 2019, 05:18 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2019 | Option Exercise | $18.43 | 806 | 14,853 | 90,081 | Oct 04, 2019, 07:58 PM |
| Quart Barry D | Chief Executive Officer | Oct 03, 2019 | Buy | $17.50 | 4,571 | 79,993 | 94,652 | Oct 04, 2019, 07:58 PM |
| POYHONEN JOHN | EVP, Chief Commercial Officer | Oct 03, 2019 | Buy | $17.50 | 5,143 | 90,003 | 18,143 | Oct 04, 2019, 07:56 PM |
| POYHONEN JOHN | Director | May 22, 2019 | Buy | $17.55 | 3,000 | 52,650 | 13,000 | May 23, 2019, 08:39 AM |
| Christian Waage | Director | May 15, 2019 | Buy | $18.04 | 1,400 | 25,262 | 1,400 | May 16, 2019, 08:44 AM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 30, 2019 | Option Exercise | $18.43 | 1,109 | 20,437 | 1,109 | May 02, 2019, 08:40 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | May 01, 2019 | Sale | $18.86 | 1,109 | 20,918 | 0 | May 02, 2019, 08:40 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 31, 2018 | Option Exercise | $23.60 | 494 | 11,656 | 494 | Nov 02, 2018, 09:17 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 02, 2018 | Sale | $30.62 | 494 | 15,125 | 0 | Nov 02, 2018, 09:17 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 01, 2018 | Option Exercise | $13.00 | 6,000 | 78,000 | 6,000 | Oct 02, 2018, 09:12 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Oct 01, 2018 | Sale | $32.07 | 6,000 | 192,433 | 0 | Oct 02, 2018, 09:12 PM |
| Quart Barry D | Chief Executive Officer | Sep 14, 2018 | Option Exercise | $7.20 | 19,675 | 141,660 | 89,275 | Sep 14, 2018, 11:41 AM |
| TANG KEVIN C | Director | Sep 12, 2018 | Sale | $35.75 | 2,695,000 | 96,346,250 | 5,830,215 | Sep 12, 2018, 12:28 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jul 02, 2018 | Option Exercise | $13.00 | 6,000 | 78,000 | 6,000 | Jul 03, 2018, 09:05 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jul 02, 2018 | Sale | $37.53 | 6,000 | 225,179 | 100 | Jul 03, 2018, 09:05 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Apr 30, 2018 | Option Exercise | $13.22 | 744 | 9,834 | 1,280 | Jul 03, 2018, 09:03 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Jul 02, 2018 | Option Exercise | $15.30 | 30,000 | 459,000 | 31,280 | Jul 03, 2018, 09:03 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Jul 02, 2018 | Sale | $38.17 | 30,000 | 1,145,230 | 2,340 | Jul 03, 2018, 09:03 PM |
| Rosen Robert | President | Jun 29, 2018 | Option Exercise | $7.20 | 129,469 | 932,177 | 132,109 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jul 02, 2018 | Option Exercise | $7.20 | 95,531 | 687,823 | 98,171 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jul 02, 2018 | Sale | $38.15 | 95,531 | 3,644,683 | 6,040 | Jul 03, 2018, 09:01 PM |
| Rosen Robert | President | Jun 29, 2018 | Sale | $39.59 | 129,469 | 5,125,135 | 56,448 | Jul 03, 2018, 09:01 PM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2018 | Option Exercise | $13.22 | 1,607 | 21,241 | 69,600 | Jun 22, 2018, 09:35 PM |
| Quart Barry D | Chief Executive Officer | Jun 21, 2018 | Option Exercise | $9.05 | 50,000 | 452,500 | 119,600 | Jun 22, 2018, 09:35 PM |
| Quart Barry D | Chief Executive Officer | Jun 21, 2018 | Sale | $39.05 | 50,000 | 1,952,500 | 69,600 | Jun 22, 2018, 09:35 PM |
| TANG KEVIN C | Director | Mar 29, 2018 | Buy | $26.00 | 192,308 | 5,000,008 | 8,525,215 | Apr 02, 2018, 04:01 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Mar 19, 2018 | Option Exercise | $13.00 | 18,000 | 234,000 | 18,000 | Mar 19, 2018, 07:24 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Mar 19, 2018 | Sale | $30.00 | 18,000 | 540,000 | 0 | Mar 19, 2018, 07:24 PM |
| Quart Barry D | Chief Executive Officer | Mar 19, 2018 | Option Exercise | $7.20 | 100,000 | 720,000 | 167,993 | Mar 19, 2018, 07:22 PM |
| Quart Barry D | Chief Executive Officer | Mar 19, 2018 | Sale | $29.75 | 100,000 | 2,975,000 | 67,993 | Mar 19, 2018, 07:22 PM |
| Quart Barry D | Chief Executive Officer | Mar 14, 2018 | Option Exercise | $7.20 | 100,000 | 720,000 | 167,993 | Mar 16, 2018, 09:00 PM |
| Quart Barry D | Chief Executive Officer | Mar 14, 2018 | Sale | $24.75 | 100,000 | 2,475,000 | 67,993 | Mar 16, 2018, 09:00 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jan 10, 2018 | Option Exercise | $13.00 | 7,584 | 98,592 | 7,584 | Jan 12, 2018, 04:21 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Jan 10, 2018 | Sale | $20.00 | 7,584 | 151,680 | 0 | Jan 12, 2018, 04:21 PM |
| Quart Barry D | Chief Executive Officer | Apr 28, 2017 | Option Exercise | $12.62 | 1,684 | 21,256 | 67,993 | Dec 20, 2017, 04:15 PM |
| HOFFMAN ROBERT | CFO & SVP, Finance | Oct 31, 2017 | Option Exercise | $13.05 | 536 | 6,993 | 536 | Dec 20, 2017, 04:13 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 24, 2017 | Option Exercise | $8.99 | 21,542 | 193,643 | 21,542 | Apr 24, 2017, 08:58 PM |
| MANHARD KIMBERLY | Executive VP, Drug Development | Apr 24, 2017 | Sale | $15.33 | 21,542 | 330,263 | 0 | Apr 24, 2017, 08:58 PM |
| POYHONEN JOHN | Director | Jan 19, 2017 | Buy | $12.20 | 10,000 | 122,000 | 10,000 | Jan 23, 2017, 04:29 PM |
| TANG KEVIN C | Director | Jan 19, 2017 | Buy | $12.20 | 2,459,016 | 29,999,995 | 8,332,907 | Jan 23, 2017, 04:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 31, 2016 | Option Exercise | $12.62 | 538 | 6,791 | 3,798 | Dec 23, 2016, 04:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Apr 29, 2016 | Option Exercise | $18.22 | 577 | 10,515 | 3,260 | Dec 23, 2016, 04:03 PM |
| Rosen Robert | President & CCO | Aug 10, 2016 | Option Exercise | $7.20 | 100,000 | 720,000 | 102,640 | Aug 12, 2016, 05:14 PM |
| Rosen Robert | President & CCO | Aug 10, 2016 | Sale | $23.30 | 100,000 | 2,329,895 | 15,040 | Aug 12, 2016, 05:14 PM |
| Quart Barry D | Chief Executive Officer | Apr 29, 2016 | Option Exercise | $18.22 | 837 | 15,253 | 61,679 | Jul 20, 2016, 08:50 AM |
| Quart Barry D | Chief Executive Officer | Jul 19, 2016 | Option Exercise | $7.20 | 4,630 | 33,336 | 66,309 | Jul 20, 2016, 08:50 AM |
| TANG KEVIN C | Director | Jun 16, 2016 | Option Exercise | $18.47 | 243,639 | 4,500,012 | 5,873,891 | Jun 20, 2016, 08:01 PM |
| TANG KEVIN C | Director | Jun 16, 2016 | Option Exercise | $3.60 | 1,250,000 | 4,500,000 | 6,117,530 | Jun 20, 2016, 08:01 PM |
| Rosen Robert | President | Apr 19, 2016 | Option Exercise | $7.20 | 176,328 | 1,269,562 | 178,968 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 21, 2016 | Option Exercise | $7.20 | 19,662 | 141,566 | 22,302 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 20, 2016 | Option Exercise | $7.20 | 4,010 | 28,872 | 6,650 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 19, 2016 | Sale | $23.38 | 176,328 | 4,122,022 | 118,043 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 21, 2016 | Sale | $22.15 | 19,662 | 435,433 | 2,640 | Apr 21, 2016, 09:27 PM |
| Rosen Robert | President | Apr 20, 2016 | Sale | $22.19 | 4,010 | 88,967 | 2,640 | Apr 21, 2016, 09:27 PM |
| Marshall Paul | SVP, Technical Operations | Mar 21, 2016 | Option Exercise | $9.05 | 1,100 | 9,955 | 2,200 | Mar 23, 2016, 03:07 PM |
| Quart Barry D | Chief Executive Officer | Mar 02, 2016 | Option Exercise | $7.20 | 3,472 | 24,998 | 60,842 | Mar 03, 2016, 08:01 AM |
| Marshall Paul | SVP, Technical Operations | Dec 29, 2015 | Option Exercise | $9.05 | 1,100 | 9,955 | 1,100 | Dec 30, 2015, 05:14 PM |
| Quart Barry D | Chief Executive Officer | Dec 28, 2015 | Option Exercise | $7.20 | 2,315 | 16,668 | 82,370 | Dec 30, 2015, 05:13 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 30, 2015 | Option Exercise | $9.36 | 714 | 6,682 | 2,683 | Dec 24, 2015, 12:29 PM |
| Drazba Brian G. | VP, Finance & CFO | Apr 30, 2015 | Option Exercise | $7.60 | 1,151 | 8,746 | 1,969 | Dec 24, 2015, 12:29 PM |
| Quart Barry D | Chief Executive Officer | Oct 14, 2015 | Option Exercise | $7.20 | 10,000 | 72,000 | 80,055 | Oct 15, 2015, 08:02 AM |
| Quart Barry D | Chief Executive Officer | Sep 29, 2015 | Option Exercise | $7.20 | 14,306 | 103,003 | 70,055 | Sep 30, 2015, 08:51 AM |
| Quart Barry D | Chief Executive Officer | Apr 30, 2015 | Option Exercise | $7.60 | 2,881 | 21,896 | 45,749 | Aug 19, 2015, 04:39 PM |
| Quart Barry D | Chief Executive Officer | Aug 18, 2015 | Option Exercise | $7.20 | 10,000 | 72,000 | 55,749 | Aug 19, 2015, 04:39 PM |
| TANG KEVIN C | Director | Jun 10, 2015 | Buy | $24.75 | 121,212 | 2,999,997 | 4,867,530 | Jun 12, 2015, 04:06 PM |
| MANHARD KIMBERLY | Director | Jun 02, 2015 | Option Exercise | $8.80 | 10,500 | 92,400 | 10,500 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 01, 2015 | Option Exercise | $9.05 | 2,708 | 24,507 | 2,708 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 02, 2015 | Sale | $23.58 | 10,500 | 247,590 | 0 | Jun 03, 2015, 06:46 PM |
| MANHARD KIMBERLY | Director | Jun 01, 2015 | Sale | $21.17 | 2,708 | 57,328 | 0 | Jun 03, 2015, 06:46 PM |
| TANG KEVIN C | Director | May 29, 2015 | Buy | $19.74 | 115,225 | 2,274,058 | 4,711,543 | Jun 02, 2015, 04:01 PM |
| TANG KEVIN C | Director | Jun 02, 2015 | Buy | $23.84 | 32,395 | 772,294 | 4,746,318 | Jun 02, 2015, 04:01 PM |
| TANG KEVIN C | Director | Jun 01, 2015 | Buy | $19.30 | 2,380 | 45,934 | 4,713,923 | Jun 02, 2015, 04:01 PM |
| Marshall Paul | SVP, Technical Operations | Mar 05, 2015 | Option Exercise | $9.40 | 70,000 | 658,000 | 70,000 | Mar 09, 2015, 07:02 PM |
| Marshall Paul | SVP, Technical Operations | Mar 05, 2015 | Sale | $14.69 | 70,000 | 1,028,000 | 20,000 | Mar 09, 2015, 07:02 PM |
| Quart Barry D | Chief Executive Officer | Mar 02, 2015 | Sale | $13.07 | 10,000 | 130,727 | 42,868 | Mar 04, 2015, 06:52 PM |
| Quart Barry D | Chief Executive Officer | Oct 31, 2014 | Option Exercise | $7.50 | 1,941 | 14,552 | 63,796 | Dec 15, 2014, 09:03 PM |
| Drazba Brian G. | VP, Finance & CFO | Oct 31, 2014 | Option Exercise | $7.50 | 818 | 6,133 | 818 | Dec 15, 2014, 08:58 PM |
| DAVIS STEPHEN | Director | Sep 26, 2014 | Option Exercise | $8.44 | 102,634 | 866,231 | 20,076 | Sep 30, 2014, 06:41 PM |
| DAVIS STEPHEN | Director | Sep 26, 2014 | Option Exercise | $7.20 | 120,313 | 866,254 | 122,710 | Sep 30, 2014, 06:41 PM |
| TANG KEVIN C | Director | Jun 25, 2014 | Buy | $11.75 | 510,638 | 5,999,997 | 4,596,318 | Jun 27, 2014, 04:01 PM |
| Quart Barry D | Chief Executive Officer | Jun 25, 2014 | Buy | $11.75 | 10,000 | 117,500 | 61,855 | Jun 26, 2014, 06:48 PM |
| TANG KEVIN C | Director | Nov 20, 2013 | Option Exercise | $0.40 | 17,500,000 | 7,000,000 | 81,713,600 | Nov 22, 2013, 05:02 PM |
| Quart Barry D | Chief Executive Officer | Nov 20, 2013 | Buy | $0.40 | 1,000,000 | 400,000 | 1,037,100 | Nov 21, 2013, 03:57 PM |
| Whelan John | CFO | Jul 18, 2013 | Option Exercise | $0.26 | 254,088 | 66,063 | 254,088 | Jul 19, 2013, 07:21 PM |
| SPCH, LLLP | 10% Owner | Jul 25, 2012 | Buy | $0.52 | 38,095,238 | 19,999,999 | 38,095,238 | Sep 12, 2012, 05:05 PM |
| TANG KEVIN C | Director | Jul 25, 2012 | Option Exercise | $0.52 | 9,523,810 | 5,000,000 | 69,960,316 | Jul 27, 2012, 07:16 PM |
| TANG KEVIN C | Director | Jun 29, 2011 | Option Exercise | $0.15 | 50,000,000 | 7,500,000 | 60,436,506 | Jul 01, 2011, 04:22 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Duarte Ira | EVP, Chief Financial Officer | 04/19/2024 | 2,962 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2024 | 1,625 |
| Forbes William P | EVP, Chief Development Officer | 11/17/2023 | 27,250 |
| Forbes William P | EVP, Chief Development Officer | 11/16/2023 | 46,995 |
| Collard Craig A | Chief Executive Officer | 11/16/2023 | 137,970 |
| Duarte Ira | EVP, Chief Financial Officer | 11/16/2023 | 75,599 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2023 | 619 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/25/2023 | 22,262 |
| Collard Craig A | Chief Executive Officer | 08/22/2023 | 1,142 |
| Morgan Adam | Director | 07/21/2023 | 3,406,839 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2023 | 2,636 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2023 | 1,127 |
| Collard Craig A | Chief Executive Officer | 05/22/2023 | 1,002 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2023 | 5,795 |
| POYHONEN JOHN | President & CCO | 04/13/2023 | 5,795 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2023 | 2,477 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2023 | 4,081 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2023 | 6,378 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/31/2022 | 5,413 |
| Quart Barry D | Chief Executive Officer | 01/13/2023 | 16,544 |
| Quart Barry D | Chief Executive Officer | 10/31/2022 | 5,416 |
| POYHONEN JOHN | President & CCO | 01/13/2023 | 6,378 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2023 | 3,211 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2023 | 6,378 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/31/2022 | 5,416 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/13/2022 | 7,565 |
| Quart Barry D | Chief Executive Officer | 10/13/2022 | 19,623 |
| POYHONEN JOHN | President & CCO | 10/13/2022 | 7,565 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2022 | 3,237 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/13/2022 | 7,565 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2022 | 6,056 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/29/2022 | 5,782 |
| Quart Barry D | Chief Executive Officer | 07/13/2022 | 15,709 |
| Quart Barry D | Chief Executive Officer | 04/29/2022 | 5,778 |
| POYHONEN JOHN | President & CCO | 07/13/2022 | 6,056 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2022 | 2,589 |
| MANHARD KIMBERLY | EVP, Drug Development | 07/13/2022 | 6,056 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/29/2022 | 5,778 |
| MANHARD KIMBERLY | EVP, Drug Development | 05/03/2022 | 7,154 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2022 | 12,213 |
| Quart Barry D | Chief Executive Officer | 04/13/2022 | 31,679 |
| POYHONEN JOHN | President & CCO | 04/13/2022 | 12,213 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2022 | 5,220 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2022 | 12,213 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2022 | 16,700 |
| Quart Barry D | Chief Executive Officer | 01/13/2022 | 43,318 |
| POYHONEN JOHN | President & CCO | 01/13/2022 | 16,700 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2022 | 8,018 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2022 | 16,700 |
| POYHONEN JOHN | President & CCO | 10/29/2021 | 7,646 |
| Christian Waage | Director | 12/21/2021 | 2,920 |
| Johnson Craig A | Director | 12/21/2021 | 2,432 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 10/13/2021 | 4,568 |
| Quart Barry D | Chief Executive Officer | 10/13/2021 | 10,160 |
| POYHONEN JOHN | President & CCO | 10/13/2021 | 4,568 |
| Peraza Lisa | VP, Chief Accounting Officer | 10/13/2021 | 2,015 |
| MANHARD KIMBERLY | EVP, Drug Development | 10/13/2021 | 4,568 |
| Christian Waage | Director | 09/21/2021 | 3,692 |
| Johnson Craig A | Director | 09/21/2021 | 3,074 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 07/13/2021 | 5,837 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/30/2021 | 21,263 |
| Quart Barry D | Chief Executive Officer | 07/13/2021 | 12,981 |
| Quart Barry D | Chief Executive Officer | 04/30/2021 | 21,249 |
| POYHONEN JOHN | President & CCO | 07/13/2021 | 5,837 |
| POYHONEN JOHN | President & CCO | 04/30/2021 | 13,494 |
| Peraza Lisa | VP, Chief Accounting Officer | 07/13/2021 | 2,575 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/30/2021 | 21,263 |
| MANHARD KIMBERLY | EVP, Drug Development | 07/13/2021 | 5,837 |
| Johnson Craig A | Director | 06/21/2021 | 3,801 |
| Christian Waage | Director | 04/15/2021 | 5,254 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 04/13/2021 | 7,214 |
| Quart Barry D | Chief Executive Officer | 04/13/2021 | 16,044 |
| POYHONEN JOHN | President & CCO | 04/13/2021 | 7,214 |
| Peraza Lisa | VP, Chief Accounting Officer | 04/13/2021 | 3,182 |
| MANHARD KIMBERLY | EVP, Drug Development | 04/13/2021 | 7,214 |
| Johnson Craig A | Director | 04/06/2021 | 4,305 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/13/2021 | 7,682 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/14/2021 | 14,960 |
| Quart Barry D | Chief Executive Officer | 01/13/2021 | 17,488 |
| POYHONEN JOHN | President & CCO | 01/13/2021 | 7,863 |
| Peraza Lisa | VP, Chief Accounting Officer | 01/13/2021 | 4,122 |
| MANHARD KIMBERLY | EVP, Drug Development | 01/13/2021 | 7,863 |
| Szekeres David Leslie | EVP, Chief Operating Officer | 01/08/2021 | 70,219 |
| POYHONEN JOHN | President & CCO | 10/30/2020 | 7,423 |
| MANHARD KIMBERLY | EVP, Drug Development | 12/22/2020 | 130,000 |
| MANHARD KIMBERLY | EVP, Drug Development | 12/22/2020 | 200,000 |
| Quart Barry D | Chief Executive Officer | 04/30/2020 | 14,036 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/30/2020 | 14,036 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 05/01/2020 | 16,176 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/29/2019 | 312,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/29/2019 | 624,000 |
| TANG KEVIN C | Director | 10/04/2019 | 4,999,995 |
| Quart Barry D | Chief Executive Officer | 04/30/2019 | 14,853 |
| Quart Barry D | Chief Executive Officer | 10/03/2019 | 79,993 |
| POYHONEN JOHN | EVP, Chief Commercial Officer | 10/03/2019 | 90,003 |
| POYHONEN JOHN | Director | 05/22/2019 | 52,650 |
| Christian Waage | Director | 05/15/2019 | 25,262 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/30/2019 | 20,437 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 05/01/2019 | 20,918 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/31/2018 | 11,656 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 11/02/2018 | 15,125 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/01/2018 | 78,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 10/01/2018 | 192,433 |
| Quart Barry D | Chief Executive Officer | 09/14/2018 | 141,660 |
| TANG KEVIN C | Director | 09/12/2018 | 96,346,250 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 07/02/2018 | 78,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 07/02/2018 | 225,179 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 04/30/2018 | 9,834 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 07/02/2018 | 459,000 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 07/02/2018 | 1,145,230 |
| Rosen Robert | President | 06/29/2018 | 932,177 |
| Rosen Robert | President | 07/02/2018 | 687,823 |
| Rosen Robert | President | 07/02/2018 | 3,644,683 |
| Rosen Robert | President | 06/29/2018 | 5,125,135 |
| Quart Barry D | Chief Executive Officer | 04/30/2018 | 21,241 |
| Quart Barry D | Chief Executive Officer | 06/21/2018 | 452,500 |
| Quart Barry D | Chief Executive Officer | 06/21/2018 | 1,952,500 |
| TANG KEVIN C | Director | 03/29/2018 | 5,000,008 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 03/19/2018 | 234,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 03/19/2018 | 540,000 |
| Quart Barry D | Chief Executive Officer | 03/19/2018 | 720,000 |
| Quart Barry D | Chief Executive Officer | 03/19/2018 | 2,975,000 |
| Quart Barry D | Chief Executive Officer | 03/14/2018 | 720,000 |
| Quart Barry D | Chief Executive Officer | 03/14/2018 | 2,475,000 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 01/10/2018 | 98,592 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 01/10/2018 | 151,680 |
| Quart Barry D | Chief Executive Officer | 04/28/2017 | 21,256 |
| HOFFMAN ROBERT | CFO & SVP, Finance | 10/31/2017 | 6,993 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/24/2017 | 193,643 |
| MANHARD KIMBERLY | Executive VP, Drug Development | 04/24/2017 | 330,263 |
| POYHONEN JOHN | Director | 01/19/2017 | 122,000 |
| TANG KEVIN C | Director | 01/19/2017 | 29,999,995 |
| Drazba Brian G. | VP, Finance & CFO | 10/31/2016 | 6,791 |
| Drazba Brian G. | VP, Finance & CFO | 04/29/2016 | 10,515 |
| Rosen Robert | President & CCO | 08/10/2016 | 720,000 |
| Rosen Robert | President & CCO | 08/10/2016 | 2,329,895 |
| Quart Barry D | Chief Executive Officer | 04/29/2016 | 15,253 |
| Quart Barry D | Chief Executive Officer | 07/19/2016 | 33,336 |
| TANG KEVIN C | Director | 06/16/2016 | 4,500,012 |
| TANG KEVIN C | Director | 06/16/2016 | 4,500,000 |
| Rosen Robert | President | 04/19/2016 | 1,269,562 |
| Rosen Robert | President | 04/21/2016 | 141,566 |
| Rosen Robert | President | 04/20/2016 | 28,872 |
| Rosen Robert | President | 04/19/2016 | 4,122,022 |
| Rosen Robert | President | 04/21/2016 | 435,433 |
| Rosen Robert | President | 04/20/2016 | 88,967 |
| Marshall Paul | SVP, Technical Operations | 03/21/2016 | 9,955 |
| Quart Barry D | Chief Executive Officer | 03/02/2016 | 24,998 |
| Marshall Paul | SVP, Technical Operations | 12/29/2015 | 9,955 |
| Quart Barry D | Chief Executive Officer | 12/28/2015 | 16,668 |
| Drazba Brian G. | VP, Finance & CFO | 10/30/2015 | 6,682 |
| Drazba Brian G. | VP, Finance & CFO | 04/30/2015 | 8,746 |
| Quart Barry D | Chief Executive Officer | 10/14/2015 | 72,000 |
| Quart Barry D | Chief Executive Officer | 09/29/2015 | 103,003 |
| Quart Barry D | Chief Executive Officer | 04/30/2015 | 21,896 |
| Quart Barry D | Chief Executive Officer | 08/18/2015 | 72,000 |
| TANG KEVIN C | Director | 06/10/2015 | 2,999,997 |
| MANHARD KIMBERLY | Director | 06/02/2015 | 92,400 |
| MANHARD KIMBERLY | Director | 06/01/2015 | 24,507 |
| MANHARD KIMBERLY | Director | 06/02/2015 | 247,590 |
| MANHARD KIMBERLY | Director | 06/01/2015 | 57,328 |
| TANG KEVIN C | Director | 05/29/2015 | 2,274,058 |
| TANG KEVIN C | Director | 06/02/2015 | 772,294 |
| TANG KEVIN C | Director | 06/01/2015 | 45,934 |
| Marshall Paul | SVP, Technical Operations | 03/05/2015 | 658,000 |
| Marshall Paul | SVP, Technical Operations | 03/05/2015 | 1,028,000 |
| Quart Barry D | Chief Executive Officer | 03/02/2015 | 130,727 |
| Quart Barry D | Chief Executive Officer | 10/31/2014 | 14,552 |
| Drazba Brian G. | VP, Finance & CFO | 10/31/2014 | 6,133 |
| DAVIS STEPHEN | Director | 09/26/2014 | 866,231 |
| DAVIS STEPHEN | Director | 09/26/2014 | 866,254 |
| TANG KEVIN C | Director | 06/25/2014 | 5,999,997 |
| Quart Barry D | Chief Executive Officer | 06/25/2014 | 117,500 |
| TANG KEVIN C | Director | 11/20/2013 | 7,000,000 |
| Quart Barry D | Chief Executive Officer | 11/20/2013 | 400,000 |
| Whelan John | CFO | 07/18/2013 | 66,063 |
| SPCH, LLLP | 10% Owner | 07/25/2012 | 19,999,999 |
| TANG KEVIN C | Director | 07/25/2012 | 5,000,000 |
| TANG KEVIN C | Director | 06/29/2011 | 7,500,000 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR
STOCK BUYBACKS FOR
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
4.35%
1Q
06/30/2023
26.38%
2Q
03/31/2023
26.88%
3Q
12/31/2022
27.00%
4Q
09/30/2022
35.41%
5Q
06/30/2022
47.75%
6Q
03/31/2022
48.15%
7Q
12/31/2021
48.31%
8Q
09/30/2021
48.47%
9Q
06/30/2021
53.67%
10Q
03/31/2021
65.56%
11Q
12/31/2020
66.11%
12Q
09/30/2020
66.54%
13Q
06/30/2020
66.72%
14Q
03/31/2020
67.35%
15Q
12/31/2019
69.63%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR
LOADING...